Wednesday, July 8, 2026

Drug profile · INN

tirofiban hydrochloride

tirofiban hydrochloride (AGGRASTAT) is a integrin alpha-iib/beta-3 inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — tirofiban hydrochloride
US status
approved
Class
Route
INJECTION
Patents
0
Programs
2
Data quality
0.84

Quick answer

tirofiban hydrochloride (AGGRASTAT) is a integrin alpha-iib/beta-3 inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN tirofiban hydrochloride
Brand AGGRASTAT
Mechanism Integrin alpha-IIb/beta-3 inhibitor
Target Integrin alpha-IIb/beta-3
Route INJECTION
Formulation INJECTABLE

Mechanism of action

Integrin alpha-IIb/beta-3 inhibitor

Primary target: Integrin alpha-IIb/beta-3

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Tirofiban Phase 3 · Universal Integrated · Acute Ischemic Stroke
  2. Tirofiban hydrochloride sodium chloride injection Approved · Chinese Academy of · Branch Atheromatous Disease

Related & competitor drugs

  1. eptifibatide Blood and blood forming organs (B01)
  2. abciximab Integrin alpha-V/beta-3 inhibitor

Frequently asked questions

What is tirofiban hydrochloride?

tirofiban hydrochloride (AGGRASTAT) is a integrin alpha-iib/beta-3 inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for tirofiban hydrochloride?

AGGRASTAT is a marketed brand name for tirofiban hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tirofiban hydrochloride?

tirofiban hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.